Pharmacokinetics of single-dose rosiglitazone in chronic ambulatory peritoneal dialysis patients

Journal of Clinical Pharmacy and Therapeutics

Volumn 33, Issue 6, 2008, Pages 685-690

  Aramwit, P ^a   Supasyndh, O ^b   Sriboonruang, T ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b PHRAMONGKUTKLAO HOSPITAL   (Thailand)

Author keywords

Chronic ambulatory peritoneal dialysis; End stage renal disease; Pharmacokinetics; Rosiglitazone

Indexed keywords

ROSIGLITAZONE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; HUMAN; KIDNEY FAILURE; MALE; MAXIMUM PLASMA CONCENTRATION; PERITONEAL DIALYSIS; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; AGED; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BLOOD PROTEINS; FEMALE; HALF-LIFE; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PROTEIN BINDING; THIAZOLIDINEDIONES; TISSUE DISTRIBUTION;

EID: 55949110268     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2008.00967.x     Document Type: Article

References (14)

1. Deckert T, Poulsen J, Larsen M (1978) Prognosis of diabetics with diabetes onset before the age of thirty-one. I. Survival, causes of death, and complications. Diabetologia, 14, 363 370.
2. Ballard D, Humphrey L, Melton L, Frohnert P, Chu P, O'fallon W, Palumbo P (1988) Epidemiology of persistent proteinuria in type II diabetes mellitus. Population-based study in Rochester, Minnesota. Diabetes, 37, 405 412.
3. Jittinun A (2002) Thailand renal replacement therapy registry 2540-2543. Journal of the Nephrology Society of Thailand, 8, 167 179.
4. Chapelsky M, Thompson-Culkin K, Miller A, Sack M, Blum R, Mi F (2003) Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency. Journal of Clinical Pharmacology, 43, 252 259.
5. Manley H, Allcock N (2003) Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis. Pharmacotherapy, 23, 861 865.
6. Henry R (1997) Thiazolidinediones. Endocrinology and Metabolism Clinics of North America, 26, 553 573.
7. Vanholder R, De Smet R, Ringoir S 1993) Factors influencing drug protein binding in patients with end stage renal failure. European Journal of Clinical Pharmacology, 44 Suppl. 1, S17 S21.
8. Thompson-Culkin K, Zussman B, Miller A, Freed M (2002) Pharmacokinetics of rosiglitazone in patients with end-stage renal disease. The Journal of International Medical Research, 30, 391 399.
9. Teitelbaum I, Burkart J (2003) Peritoneal dialysis. American Journal of Kidney Diseases, 42, 1082 1096.
10. Sripalakit P, Neamhom P, Saraphanchotiwitthaya A (2006) High-performance liquid chromatographic method for the determination of pioglitazone in human plasma using ultraviolet detection and its application to a pharmacokinetic study. Journal of Chromatography B, An Analytical Technologies in the Biomedical and Life Sciences, 843, 164 169.
11. Harrower A (1996) Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency. Clinical Pharmacokinetics, 31, 111 119.
12. Tan M 2000) Current treatment of insulin resistance in type 2 diabetes mellitus. International Journal of Clinical Practice Supplement, 113, 54 62.
13. Schneiderman J, Sawdey M, Keeton M, Bordin G, Bernstein E, Dilley R, Loskutoff D (1992) Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proceedings of the National Academy of Sciences of the United States of America, 89, 6998 7002.
14. Chomiki N, Henry M, Alessi M, Anfosso F, Juhan-Vague I (1994) Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls. Thrombosis and Haemostasis, 72, 44 53.